DNMT3A and Splenomegaly: Both genotypes confer a significantly shorter survival time compared to Flt3ITD/+ mice alone, which have a median survival of 412 days, consistent with our previous findings.[4, 20, 21] Dnmt3a dosage was also associated with a number of other parameters, including splenomegaly (Figure 1C) and leukocytosis (Figure 1D).